177 related articles for article (PubMed ID: 31807295)
1. Clinical features and outcomes in a cohort of patients with immunoglobulin G4-related disease at a university hospital in Spain.
Quero M; Draibe J; Solanich X; Rama I; Gomà M; Martínez-Valenzuela L; Fulladosa X; Cruzado JM; Torras J
Clin Kidney J; 2019 Dec; 12(6):829-835. PubMed ID: 31807295
[TBL] [Abstract][Full Text] [Related]
2. IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients.
Campochiaro C; Ramirez GA; Bozzolo EP; Lanzillotta M; Berti A; Baldissera E; Dagna L; Praderio L; Scotti R; Tresoldi M; Roveri L; Mariani A; Balzano G; Castoldi R; Doglioni C; Sabbadini MG; Della-Torre E
Scand J Rheumatol; 2016; 45(2):135-45. PubMed ID: 26398142
[TBL] [Abstract][Full Text] [Related]
3. IgG4-related uveitis. A French cohort and literature review.
Stuchfield-Denby E; De Sainte Marie B; Hie M; Hatchuel Y; Gerber A; Bencheikh S; Pugnet G; Groh M; Farhat MM; Urbina D; Ebbo M; Schleinitz N
Semin Arthritis Rheum; 2024 Feb; 64():152278. PubMed ID: 38000318
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and outcome of IgG4-related disease with hypocomplementemia: a prospective cohort study.
Peng L; Lu H; Zhou J; Zhang P; Li J; Liu Z; Wu D; Zhang S; Yang Y; Bai W; Wang L; Fei Y; Zhang W; Zhao Y; Zeng X; Zhang F
Arthritis Res Ther; 2021 Apr; 23(1):102. PubMed ID: 33827676
[TBL] [Abstract][Full Text] [Related]
5. Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease.
Majumder S; Mohapatra S; Lennon RJ; Piovezani Ramos G; Postier N; Gleeson FC; Levy MJ; Pearson RK; Petersen BT; Vege SS; Chari ST; Topazian MD; Witzig TE
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1947-1953. PubMed ID: 29526692
[TBL] [Abstract][Full Text] [Related]
6. Addition of second-line steroid sparing immunosuppressants like mycophenolate mofetil improves outcome of Immunoglobulin G4-related disease (IgG4-RD): a series from a tertiary care teaching hospital in South India.
Gupta N; Mathew J; Mohan H; Chowdhury SD; Kurien RT; Christopher DJ; Thangakunam B; Alexander M; Sivadasan A; Tamilarasi V; Valson AT; Gowri M; Kabeerdoss J; Danda D
Rheumatol Int; 2018 Feb; 38(2):203-209. PubMed ID: 28550399
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological Patterns and Predictors of the Functional Restoration of Immunoglobulin G4-Related Kidney Disease: A Chinese Single-Center Cohort Study.
Su T; Wang H; Wang S; Yang L
Front Med (Lausanne); 2021; 8():736098. PubMed ID: 34692728
[No Abstract] [Full Text] [Related]
8. A Follow-Up Study of a European IgG4-Related Disease Cohort Treated with Rituximab.
Backhus J; Neumann C; Perkhofer L; Schulte LA; Mayer B; Seufferlein T; Müller M; Kleger A
J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33807051
[TBL] [Abstract][Full Text] [Related]
9. Treatment and outcomes in patients with IgG4-related disease using the IgG4 responder index.
Fernández-Codina A; Pinilla B; Pinal-Fernández I; López C; Fraile-Rodríguez G; Fonseca-Aizpuru E; Carballo I; Brito-Zerón P; Feijóo-Massó C; López-Dupla M; Cid MC; Martínez-Valle F; ; ;
Joint Bone Spine; 2018 Dec; 85(6):721-726. PubMed ID: 29452298
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy of leflunomide and glucocorticoids for the maintenance of remission in patients with IgG4-related disease: a retrospective study and literature review.
Wang Y; Li K; Gao D; Luo G; Zhao Y; Wang X; Zhang J; Jin J; Zhao Z; Yang C; Zhu J; Zhang J; Huang F
Intern Med J; 2017 Jun; 47(6):680-689. PubMed ID: 28321964
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin G4-related Disease: A New Systemic Disease Emerging in Japan.
Kamisawa T
JMA J; 2022 Jan; 5(1):23-35. PubMed ID: 35224257
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study.
Della-Torre E; Lanzillotta M; Campochiaro C; Di-Colo G; Mancuso G; Capurso G; Falconi M; Dagna L
Eur J Intern Med; 2021 Feb; 84():63-67. PubMed ID: 33386207
[TBL] [Abstract][Full Text] [Related]
13. Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes.
Lanzillotta M; Campochiaro C; Mancuso G; Ramirez GA; Capurso G; Falconi M; Dagna L; Della-Torre E
Rheumatology (Oxford); 2020 Sep; 59(9):2435-2442. PubMed ID: 32591828
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Effects of Cyclophosphamide and Mycophenolate Mofetil Treatment Against Immunoglobulin G4-Related Disease: A Retrospective Cohort Study.
Luo X; Peng Y; Zhang P; Li J; Liu Z; Lu H; Zhang X; Zeng X; Zhang F; Fei Y; Zhang W
Front Med (Lausanne); 2020; 7():253. PubMed ID: 32733900
[No Abstract] [Full Text] [Related]
15. IgG4-Related Disease: Clinical and Laboratory Features in One Hundred Twenty-Five Patients.
Wallace ZS; Deshpande V; Mattoo H; Mahajan VS; Kulikova M; Pillai S; Stone JH
Arthritis Rheumatol; 2015 Sep; 67(9):2466-75. PubMed ID: 25988916
[TBL] [Abstract][Full Text] [Related]
16. Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial.
Peng L; Nie Y; Zhou J; Wu L; Chen X; Wang F; Li J; Peng Y; Lu H; Zhao L; Li M; Zhao Y; Zeng X; Fei Y; Zhang W
Ann Rheum Dis; 2024 Apr; 83(5):651-660. PubMed ID: 38216319
[TBL] [Abstract][Full Text] [Related]
17. IgG4-related disease in a multi-ethnic community: clinical characteristics and association with malignancy.
Poo SX; Tham CSW; Smith C; Lee J; Cairns T; Galliford J; Hamdulay S; Jacyna M; Levy JB; McAdoo SP; Roufosse C; Wernig F; Mason JC; Pusey CD; Tam FWK; Tomlinson JAP
QJM; 2019 Oct; 112(10):763-769. PubMed ID: 31225617
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for IgG4-related disease: a prospective, open-label trial.
Carruthers MN; Topazian MD; Khosroshahi A; Witzig TE; Wallace ZS; Hart PA; Deshpande V; Smyrk TC; Chari S; Stone JH
Ann Rheum Dis; 2015 Jun; 74(6):1171-7. PubMed ID: 25667206
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Uses of Rituximab and Clinical Features in Immunoglobulin G4-Related Disease: A Systematic Review.
Patel U; Saxena A; Patel D; Ayesha IE; Monson NR; Klair N; Yu AK
Cureus; 2023 Sep; 15(9):e45044. PubMed ID: 37701160
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease.
Liu Y; Zhang Y; Bian W; Fu J; Sun X; Chen D; Chen J; Zhao X; Li Y; Zhang W; Li Z
Clin Rheumatol; 2020 Feb; 39(2):491-497. PubMed ID: 31848912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
